Research programme: analgesic therapeutic - Cassava Sciences/University of Texas at Austin
Latest Information Update: 28 Feb 2023
At a glance
- Originator Pain Therapeutics
- Developer Cassava Sciences; University of Texas at Austin
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Pain in USA
- 27 Mar 2019 Pain Therapeutics is now called Cassava Sciences
- 17 Jan 2019 Pain Therapeutics and University of Texas at Austin enters into an academic collaboration for development of a product candidate for Pain